Genetic and molecular epidemiology of multiple myeloma

Por Lentzsch, Suzanne.
Publicado em 2013

Metastatic Breast Cancer or Multiple Myeloma? Camouflage by Lytic Lesions

Por Hough, Bruce, Brufsky, Adam, Lentzsch, Suzanne
Publicado em 2010

Pomalidomide is strongly antiangiogenic and teratogenic in relevant animal models

Por D’Amato, Robert J., Lentzsch, Suzanne, Rogers, Michael S.
Publicado em 2013

Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist

Por Raza, Shahzad, Safyan, Rachael A., Rosenbaum, Evan, Bowman, Alex S., Lentzsch, Suzanne
Publicado no Ther Adv Hematol (2016)

Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation

Por Xu, Guoshuang, Liu, Kai, Anderson, Judy, Patrene, Kenneth, Lentzsch, Suzanne, Roodman, G. David, Ouyang, Hongjiao
Publicado em 2012

Longitudinal bone marrow evaluations for myelodysplasia in myeloma patients before and after treatment with lenalidomide

Por Monaghan, Sara A., Dai, Lijun, Mapara, Markus Y., Normolle, Daniel P., Gollin, Susanne M., Lentzsch, Suzanne
Publicado em 2013

Absence of Stat1 in donor CD4(+) T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice

Por Ma, Huihui, Lu, Caisheng, Ziegler, Judith, Liu, Ailing, Sepulveda, Antonia, Okada, Hideho, Lentzsch, Suzanne, Mapara, Markus Y.
Publicado em 2011

Sequential Activation of Inflammatory Signaling Pathways During Graft-versus-Host Disease (GVHD): Early Role for STAT1 and STAT3

Por Ma, Hui-Hui, Ziegler, Judy, Li, Cuiling, Sepulveda, Antonia, Bedeir, Ahmed, Grandis, Jennifer, Lentzsch, Suzanne, Mapara, Markus Y.
Publicado em 2011

IMiD immunomodulatory compounds block C/EBPβ translation through eIF4E down-regulation resulting in inhibition of MM

Por Li, Shirong, Pal, Rekha, Monaghan, Sara A., Schafer, Peter, Ouyang, Hongjiao, Mapara, Markus, Galson, Deborah L., Lentzsch, Suzanne
Publicado em 2011

Targeting Cannabinoid Receptor-2 Pathway by Phenylacetylamide Suppresses the Proliferation of Human Myeloma Cells Through Mitotic Dysregulation and Cytoskeleton Disruption

Por Feng, Rentian, Tong, Qin, Xie, Zhaojun, Cheng, Haizi, Wang, Lirong, Lentzsch, Suzanne, Roodman, G. David, Xie, Xiang-Qun
Publicado no Mol Carcinog (2015)

The B lineage transcription factor E2A regulates apoptosis in chronic lymphocytic leukemia (CLL) cells

Por Kardava, Lela, Yang, Qi, St. Leger, Anthony, Foon, Kenneth A., Lentzsch, Suzanne, Vallejo, Abbe N., Milcarek, Christine, Borghesi, Lisa
Publicado em 2011

C/EBPβ regulates transcription factors critical for proliferation and survival of multiple myeloma cells

Por Pal, Rekha, Janz, Martin, Galson, Deborah L., Gries, Margarete, Li, Shirong, Jöhrens, Korinna, Anagnostopoulos, Ioannis, Dörken, Bernd, Mapara, Markus Y., Borghesi, Lisa, Kardava, Lela, Roodman, G. David, Milcarek, Christine, Lentzsch, Suzanne
Publicado em 2009

Multiple myeloma–derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease

Por Fu, Jing, Li, Shirong, Feng, Rentian, Ma, Huihui, Sabeh, Farideh, Roodman, G. David, Wang, Ji, Robinson, Samuel, Guo, X. Edward, Lund, Thomas, Normolle, Daniel, Mapara, Markus Y., Weiss, Stephen J., Lentzsch, Suzanne
Publicado no J Clin Invest (2016)

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 o...

Por Lentzsch, Suzanne, O'Sullivan, Amy, Kennedy, Ryan C., Abbas, Mohammad, Dai, Lijun, Pregja, Silvana Lalo, Burt, Steve, Boyiadzis, Michael, Roodman, G. David, Mapara, Markus Y., Agha, Mounzer, Waas, John, Shuai, Yongli, Normolle, Daniel, Zonder, Jeffrey A.
Publicado em 2012

Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma

Por Shah, Jatin J., Stadtmauer, Edward A., Abonour, Rafat, Cohen, Adam D., Bensinger, William I., Gasparetto, Cristina, Kaufman, Jonathan L., Lentzsch, Suzanne, Vogl, Dan T., Gomes, Christina L., Pascucci, Natalia, Smith, David D., Orlowski, Robert Z., Durie, Brian G. M.
Publicado no Blood (2015)

International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease

Por Terpos, Evangelos, Morgan, Gareth, Dimopoulos, Meletios A., Drake, Matthew T., Lentzsch, Suzanne, Raje, Noopur, Sezer, Orhan, García-Sanz, Ramón, Shimizu, Kazuyuki, Turesson, Ingemar, Reiman, Tony, Jurczyszyn, Artur, Merlini, Giampaolo, Spencer, Andrew, Leleu, Xavier, Cavo, Michele, Munshi, Nikhil, Rajkumar, S. Vincent, Durie, Brian G.M., Roodman, G. David
Publicado no J Clin Oncol (2013)

Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies

Por Deng, Changchun, Lipstein, Mark R., Scotto, Luigi, Jirau Serrano, Xavier O., Mangone, Michael A., Li, Shirong, Vendome, Jeremie, Hao, Yun, Xu, Xiaoming, Deng, Shi-Xian, Realubit, Ronald B., Tatonetti, Nicholas P., Karan, Charles, Lentzsch, Suzanne, Fruman, David A., Honig, Barry, Landry, Donald W., O’Connor, Owen A.
Publicado no Blood (2017)

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

Por Richardson, Paul G., Siegel, David S., Vij, Ravi, Hofmeister, Craig C., Baz, Rachid, Jagannath, Sundar, Chen, Christine, Lonial, Sagar, Jakubowiak, Andrzej, Bahlis, Nizar, Song, Kevin, Belch, Andrew, Raje, Noopur, Shustik, Chaim, Lentzsch, Suzanne, Lacy, Martha, Mikhael, Joseph, Matous, Jeffrey, Vesole, David, Chen, Min, Zaki, Mohamed H., Jacques, Christian, Yu, Zhinuan, Anderson, Kenneth C.
Publicado em 2014